Loading organizations...
Based in Tokyo, Japan, Cosomil develops blood-based diagnostic tests for the early detection of cancer utilizing its proprietary Single Enzyme Activity-based Protein Profiling technology. The biotechnology startup focuses on high-precision liquid biopsies to identify diseases such as pancreatic and colorectal cancer by analyzing enzyme activity at the single-molecule level with fluorescent probes and microdevices. Backed by pre-Series A funding from lead investor ANRI Inc., the company operates with approximately $400,000 USD in capital to advance its diagnostic laboratory developed tests, home test kits, and drug development support services. Supported by the NEDO globalization program, the firm is preparing to conduct clinical studies in the United States involving roughly 1,000 participants while pursuing Breakthrough Device Designation from the FDA and planning consultations with the PMDA. Cosomil was founded in 2022 by Yu Kagami and Shingo Sakamoto.
Cosomil employs single-molecule enzyme activity imaging technology to develop highly sensitive blood-based tests for early disease detection. This method allows for precise analysis of enzyme activity, which can indicate the presence of diseases like cancer.
Yes, Cosomil has collaborated with institutions such as Osaka Metropolitan University to advance the detection of specific cancers, including hepatobiliary pancreatic cancers. This partnership highlights their commitment to scientific progress in diagnostic development.
Cosomil was founded by Yu Kagami, PhD, who currently serves as the company's CEO. Dr. Kagami leads the company's efforts in pioneering early cancer detection through single-molecule enzyme activity-based liquid biopsy.
Cosomil employs single-molecule enzyme activity imaging technology to develop highly sensitive blood-based tests for early disease detection. This method allows for precise analysis of enzyme activity, which can indicate the presence of diseases like cancer.
Yes, Cosomil has collaborated with institutions such as Osaka Metropolitan University to advance the detection of specific cancers, including hepatobiliary pancreatic cancers. This partnership highlights their commitment to scientific progress in diagnostic development.
Cosomil was founded by Yu Kagami, PhD, who currently serves as the company's CEO. Dr. Kagami leads the company's efforts in pioneering early cancer detection through single-molecule enzyme activity-based liquid biopsy.
Cosomil, Inc. is a pharmaceutical company established in 2022, specializing in the research and development of advanced diagnostic methods for early-stage diseases, particularly cancer. Headquartered in Tokyo, Japan, the company is focused on creating innovative solutions that enable the detection of various cancers at their initial stages, which is crucial for effective treatment and improved patient prognoses.
The core of Cosomil's diagnostic approach involves leveraging sophisticated technologies, including single-molecule enzyme activity imaging. This method allows for highly sensitive and precise analysis of enzyme activity, which can serve as an early indicator of disease presence. The company is developing blood-based tests, often referred to as liquid biopsies, to facilitate non-invasive and accessible early detection.
Cosomil actively engages in collaborative research to further its diagnostic capabilities. An example includes a partnership with Osaka Metropolitan University, aimed at advancing the detection of hepatobiliary pancreatic cancers. These collaborations underscore the company's commitment to scientific progress and addressing challenging disease areas.
The company was founded by Yu Kagami, PhD, who serves as its CEO. Dr. Kagami's leadership emphasizes pioneering early cancer detection through single-molecule enzyme activity-based liquid biopsy. This foundational expertise guides Cosomil's strategic direction in developing its diagnostic platforms.
By focusing on the development of highly sensitive and specific diagnostic tools, Cosomil aims to significantly impact public health. The ability to detect diseases like cancer at their earliest stages can lead to more timely medical interventions, potentially reducing mortality rates and enhancing the quality of life for patients. Cosomil continues to pursue its mission to make early and accurate disease diagnosis widely accessible.
Cosomil most recently raised Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 6, 2026 | Series A | Delight Ventures | Animal Spirits Ltd., ANRI, Gogin Capital, Green Core | Announced |